IL162648A0 - Cellular compositions and methods of making and using them - Google Patents
Cellular compositions and methods of making and using themInfo
- Publication number
- IL162648A0 IL162648A0 IL16264802A IL16264802A IL162648A0 IL 162648 A0 IL162648 A0 IL 162648A0 IL 16264802 A IL16264802 A IL 16264802A IL 16264802 A IL16264802 A IL 16264802A IL 162648 A0 IL162648 A0 IL 162648A0
- Authority
- IL
- Israel
- Prior art keywords
- cellular compositions
- methods
- cells
- making
- hematopoietic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/12—Hepatocyte growth factor [HGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34258601P | 2001-12-21 | 2001-12-21 | |
PCT/CA2002/001979 WO2003055989A2 (fr) | 2001-12-21 | 2002-12-20 | Compositions cellulaires et procedes de preparation et d'utilisation associes |
Publications (1)
Publication Number | Publication Date |
---|---|
IL162648A0 true IL162648A0 (en) | 2005-11-20 |
Family
ID=23342451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16264802A IL162648A0 (en) | 2001-12-21 | 2002-12-20 | Cellular compositions and methods of making and using them |
Country Status (9)
Country | Link |
---|---|
US (3) | US7625752B2 (fr) |
EP (1) | EP1458854B1 (fr) |
JP (1) | JP2005512592A (fr) |
AT (1) | ATE464373T1 (fr) |
AU (1) | AU2002350352A1 (fr) |
CA (1) | CA2470707C (fr) |
DE (1) | DE60236016D1 (fr) |
IL (1) | IL162648A0 (fr) |
WO (1) | WO2003055989A2 (fr) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080152629A1 (en) * | 2000-12-06 | 2008-06-26 | James Edinger | Placental stem cell populations |
EP1349918B1 (fr) * | 2000-12-06 | 2014-08-06 | Anthrogenesis Corporation | Technique de recueil de cellules souches placentaires |
US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
ES2522526T3 (es) | 2001-02-14 | 2014-11-14 | Anthrogenesis Corporation | Placenta post-parto de mamíferos, su uso y células troncales placentarias de la misma |
US7129034B2 (en) * | 2001-10-25 | 2006-10-31 | Cedars-Sinai Medical Center | Differentiation of whole bone marrow |
JP2005512592A (ja) * | 2001-12-21 | 2005-05-12 | マウント・シナイ・ホスピタル | 細胞性組成物ならびに細胞性組成物の作製法および細胞性組成物の使用法 |
CN1717177A (zh) * | 2002-11-26 | 2006-01-04 | 人类起源公司 | 细胞治疗剂、细胞治疗单元及其用于治疗的方法 |
US7875272B2 (en) * | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
WO2005001079A2 (fr) | 2003-06-27 | 2005-01-06 | Ethicon, Incorporated | Reparation et regeneration des tissus mous a l'aide de cellules provenant de tissus post-partum |
US8491883B2 (en) * | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US20100158880A1 (en) * | 2008-12-19 | 2010-06-24 | Ethicon, Incorporated | Regeneration and repair of neural tissue following injury |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
GB0329449D0 (en) * | 2003-12-19 | 2004-01-28 | Omnicyte Ltd | Stem cells |
WO2005073366A1 (fr) | 2004-01-30 | 2005-08-11 | Lifecord Inc. | Methode d'isolement et de culture de cellules souches multipotentes a partir de sang du cordon ombilical et procede pour induire leur differenciation |
EP1735429A4 (fr) * | 2004-03-31 | 2008-06-11 | Newlink Genetics Corp | Procedes et compositions destines a l'obtention de cellules souches hematopoietiques derivees de cellules souches embryonnaires et utilisations |
EP1747265B1 (fr) * | 2004-04-23 | 2011-04-20 | BioE LLC | Cellules précurseurs de plusieurs lignages |
US7622108B2 (en) * | 2004-04-23 | 2009-11-24 | Bioe, Inc. | Multi-lineage progenitor cells |
DK2292733T3 (da) * | 2004-12-14 | 2020-01-13 | Kwalata Trading Ltd | Fremstilling ud fra blod af celler af nervecellelinje |
US20060166361A1 (en) * | 2004-12-21 | 2006-07-27 | Agnieszka Seyda | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
WO2006101548A2 (fr) * | 2004-12-21 | 2006-09-28 | Ethicon, Inc. | Cellules post-partum derivees du tissu du cordon ombilical et leurs procedes de fabrication, de mise en culture et d'utilisation |
US20060153815A1 (en) * | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
JP5425400B2 (ja) | 2004-12-23 | 2014-02-26 | エシコン・インコーポレイテッド | 産褥由来細胞を用いた脳卒中および他の急性神経変性障害の治療 |
JP5340599B2 (ja) | 2004-12-23 | 2013-11-13 | エシコン・インコーポレイテッド | 臍帯組織由来産褥細胞ならびにその製造方法および使用方法 |
US9388382B2 (en) | 2005-10-05 | 2016-07-12 | The Board Of Trustees Of The University Of Illinois | Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells |
PE20070771A1 (es) | 2005-10-13 | 2007-08-11 | Anthrogenesis Corp | Inmunomodulacion mediante el uso de celulas madres de la placenta |
EP4223769A3 (fr) * | 2005-12-13 | 2023-11-01 | Kyoto University | Facteur de reprogrammation nucléaire |
AU2006325710B2 (en) * | 2005-12-16 | 2012-05-17 | Ethicon, Inc. | Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
EP1976975B1 (fr) * | 2005-12-19 | 2012-08-01 | Ethicon, Inc. | Methode d'expansion in vitro de cellules derivees de tissus puerperaux mise en oeuvre dans des flacons pour agitateurs rotatifs |
ES2628129T3 (es) * | 2005-12-28 | 2017-08-01 | DePuy Synthes Products, Inc. | Tratamiento de la enfermedad vascular periférica utilizando células derivadas del posparto |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
EP2471904B1 (fr) | 2005-12-29 | 2018-10-24 | Celularity, Inc. | Populations de cellules souches placentaires |
CA2633775A1 (fr) * | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture de cellules souches placentaires et cellules souches provenant d'une seconde source |
TW200734462A (en) | 2006-03-08 | 2007-09-16 | In Motion Invest Ltd | Regulating stem cells |
RU2493252C2 (ru) * | 2006-03-24 | 2013-09-20 | Чилдрен'З Медикал Сентер Корпорейшн | Способ стимулирования экспансии гематопоэтических стволовых клеток |
CA2646491A1 (fr) * | 2006-04-17 | 2007-10-25 | Bioe, Inc. | Differenciation des cellules progenitrices a lignees multiples et cellules epitheliales respiratoires |
CA2666789C (fr) | 2006-10-18 | 2016-11-22 | Yong Zhao | Cellules souches de type embryonnaire derivees du sang peripherique d'un etre humain adulte et procedes d'utilisation associes |
JP5426389B2 (ja) | 2006-10-20 | 2014-02-26 | チルドレンズ メディカル センター コーポレーション | 組織の再生を亢進するための方法 |
PL2084268T3 (pl) * | 2006-10-23 | 2019-08-30 | Celularity, Inc. | Sposoby i kompozycje do leczenia ubytków kości z użyciem populacji komórek łożyska |
NZ597779A (en) | 2007-02-12 | 2013-07-26 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
US20100143476A1 (en) * | 2007-02-14 | 2010-06-10 | March Keith L | Composition for stimulating formation of vascular structures |
WO2008104065A1 (fr) * | 2007-02-26 | 2008-09-04 | Mount Sinai Hospital | Préparations de cellules neuronales et procédés de production et d'utilisation correspondants |
US20100158874A1 (en) * | 2007-02-26 | 2010-06-24 | Mount Sinai Hospital | Compositions and Methods for Treating Peripheral Vascular Diseases |
EP2137297A4 (fr) * | 2007-04-11 | 2010-04-14 | Roger Deutsch | Procédés de diagnostic d'échantillons biologiques contenant des cellules souches |
US20080318314A1 (en) * | 2007-06-20 | 2008-12-25 | Valentin Fulga | Production from blood of cells of neural lineage |
US9404084B2 (en) | 2007-06-20 | 2016-08-02 | Kwalata Trading Limited | Regulating stem cells |
CN101835479A (zh) * | 2007-07-25 | 2010-09-15 | 佰欧益有限公司 | 多系祖细胞分化为软骨细胞 |
AU2008308531B2 (en) * | 2007-10-05 | 2014-04-24 | Ethicon, Incorporated | Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells |
US8236538B2 (en) | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
ES2665017T3 (es) * | 2008-03-20 | 2018-04-24 | University Of Florida Research Foundation, Inc. | Mejorar el potencial de retorno y reparación de células madre en lesiones vasculares |
WO2009143241A2 (fr) * | 2008-05-21 | 2009-11-26 | Bioe, Inc. | Différenciation de cellules progénitrices de multiples lignées en cellules pancréatiques |
US20110206781A1 (en) * | 2008-05-28 | 2011-08-25 | Zon Leonard I | Method to modulate hematopoietic stem cell growth |
US8728805B2 (en) | 2008-08-22 | 2014-05-20 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
GB0818725D0 (en) | 2008-10-13 | 2008-11-19 | Habib Nagy A | Pharmaceutical composition |
CN107028983A (zh) | 2008-12-19 | 2017-08-11 | 德普伊新特斯产品有限责任公司 | 肺部疾病和病症的治疗 |
US10179900B2 (en) * | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
BRPI0923177A2 (pt) * | 2008-12-19 | 2020-08-25 | Advanced Technologies And Regenerative Medicine, Llc | usos de composições para tratar dor neuropática e espacidade, as referidas composições, e kit |
US9056085B2 (en) | 2009-02-03 | 2015-06-16 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
WO2010091052A2 (fr) | 2009-02-03 | 2010-08-12 | Children's Medical Center Corporation | Procédés de renforcement de greffe de cellule souche hématopoïétique/progénitrice |
KR101720961B1 (ko) * | 2009-02-27 | 2017-03-29 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | 다능성 세포의 분화 |
US8722034B2 (en) * | 2009-03-26 | 2014-05-13 | Depuy Synthes Products Llc | hUTC as therapy for Alzheimer's disease |
WO2011127113A1 (fr) | 2010-04-08 | 2011-10-13 | Anthrogenesis Corporation | Traitement de la sarcoïdose au moyen de cellules souches du sang placentaire |
WO2011143411A1 (fr) * | 2010-05-12 | 2011-11-17 | Abt Holding Company | Modulation des splénocytes en thérapie cellulaire pour une lésion cérébrale traumatique |
CA3128483A1 (fr) | 2010-05-12 | 2011-11-17 | Abt Holding Company | Modulation des splenocytes en therapie cellulaire |
US9163234B2 (en) | 2010-10-06 | 2015-10-20 | Omnicyte Limited | Culture method |
WO2012048275A2 (fr) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Procédés et systèmes configurables pour la culture et la récolte de cellules dans un système de bioréacteur à fibres creuses |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
JP6190723B2 (ja) | 2010-12-01 | 2017-08-30 | アルダーバイオ ホールディングス エルエルシー | 抗ngf組成物およびその使用 |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
WO2012092485A1 (fr) | 2010-12-31 | 2012-07-05 | Anthrogenesis Corporation | Amélioration de l'efficacité de cellules souches placentaires sous l'effet de molécules d'arn modulateur |
US20130331326A1 (en) * | 2011-02-21 | 2013-12-12 | Duke University | Method of inducing hematopoietic reconstruction |
AU2012262273B2 (en) | 2011-06-01 | 2017-09-14 | Celularity Inc. | Treatment of pain using placental stem cells |
WO2013055476A1 (fr) | 2011-09-09 | 2013-04-18 | Anthrogenesis Corporation | Traitement de la sclérose latérale amyotrophique au moyen de cellules souches placentaires |
EP2785350B1 (fr) | 2011-12-02 | 2018-05-02 | Fate Therapeutics, Inc. | Méthodes améliorées permettant de traiter l'ischémie |
EP3785767A1 (fr) | 2011-12-02 | 2021-03-03 | Fate Therapeutics, Inc. | Composition améliorée de cellules souches |
AU2012358810B2 (en) | 2011-12-23 | 2018-03-15 | DePuy Synthes Products, Inc. | Detection of human umbilical cord tissue-derived cells |
WO2014150602A1 (fr) | 2013-03-15 | 2014-09-25 | Fate Therapeutics, Inc. | Essai d'activité biologique de cellules pour un potentiel thérapeutique |
US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
EP2796545A1 (fr) * | 2013-04-26 | 2014-10-29 | Université Pierre et Marie Curie (Paris 6) | Procédés d'obtention de progéniteurs rétiniens, cellules de l'épithélium rétinien pigmenté et cellules rétiniennes neuronales |
WO2015073751A1 (fr) * | 2013-11-15 | 2015-05-21 | Applied Stemcell, Inc. | Méthodes d'isolation de cellules spécifiques d'une lignée |
JP6633522B2 (ja) | 2013-11-16 | 2020-01-22 | テルモ ビーシーティー、インコーポレーテッド | バイオリアクターにおける細胞増殖 |
JP2017506511A (ja) * | 2014-02-14 | 2017-03-09 | ナショナル ユニバーシティー オブ アイルランド, ゴールウェイ | 無血清培地 |
WO2015148704A1 (fr) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Remplacement passif de milieu |
JP6830059B2 (ja) | 2014-09-26 | 2021-02-17 | テルモ ビーシーティー、インコーポレーテッド | スケジュール化された細胞フィーディング |
WO2017004592A1 (fr) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Croissance cellulaire à l'aide de stimuli mécaniques |
WO2017205667A1 (fr) | 2016-05-25 | 2017-11-30 | Terumo Bct, Inc. | Expansion cellulaire |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
WO2019055817A1 (fr) * | 2017-09-14 | 2019-03-21 | The Regents Of The University Of California | Conservation et expansion ex vivo de cellules souches |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091206A (en) * | 1987-10-26 | 1992-02-25 | Baxter Diagnostics Inc. | Process for producing magnetically responsive polymer particles and application thereof |
US5677136A (en) * | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
US5665557A (en) * | 1994-11-14 | 1997-09-09 | Systemix, Inc. | Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof |
US5728581A (en) * | 1995-06-07 | 1998-03-17 | Systemix, Inc. | Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein |
AU5083098A (en) * | 1996-10-25 | 1998-05-22 | Icogen Corporation | Use of leptin to stimulate hematopoiesis |
US20020155108A1 (en) * | 1998-05-04 | 2002-10-24 | Biocrystal, Ltd. | Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells |
DK1082410T3 (da) | 1998-05-29 | 2007-11-26 | Osiris Therapeutics Inc | Humane CD45 - og/eller fibroblast mesenchymale stamceller |
AU6056299A (en) * | 1998-09-21 | 2000-04-10 | Musc Foundation For Research Development | Non-hematopoietic cells, including cardiomyocytes and skeletal muscle cells, derived from hematopoietic stem cells and methods of making and using them |
EP1218487A2 (fr) | 1999-09-23 | 2002-07-03 | Cell Science Therapeutics | Procedes et dispositifs permettant d'obtenir des cellules de lignee non hematopoietique a partir de cellules de progeniteurs hematopoietiques |
JP2004500824A (ja) * | 2000-03-09 | 2004-01-15 | クリオ−セル インターナショナル インコーポレーティッド | 脳および脊髄の修復のための神経組織源としてのヒト臍帯血 |
AU2001250966A1 (en) | 2000-03-23 | 2001-10-03 | Stem Cells, Inc. | Pluripotential stem cells |
KR20050042046A (ko) * | 2001-10-30 | 2005-05-04 | 다이이찌 세이야꾸 가부시기가이샤 | 조혈 줄기세포의 증식방법 |
JP2005512592A (ja) * | 2001-12-21 | 2005-05-12 | マウント・シナイ・ホスピタル | 細胞性組成物ならびに細胞性組成物の作製法および細胞性組成物の使用法 |
EP1735429A4 (fr) * | 2004-03-31 | 2008-06-11 | Newlink Genetics Corp | Procedes et compositions destines a l'obtention de cellules souches hematopoietiques derivees de cellules souches embryonnaires et utilisations |
US20100158874A1 (en) * | 2007-02-26 | 2010-06-24 | Mount Sinai Hospital | Compositions and Methods for Treating Peripheral Vascular Diseases |
-
2002
- 2002-12-20 JP JP2003556509A patent/JP2005512592A/ja active Pending
- 2002-12-20 DE DE60236016T patent/DE60236016D1/de not_active Expired - Lifetime
- 2002-12-20 IL IL16264802A patent/IL162648A0/xx unknown
- 2002-12-20 EP EP02784995A patent/EP1458854B1/fr not_active Expired - Lifetime
- 2002-12-20 CA CA2470707A patent/CA2470707C/fr not_active Expired - Fee Related
- 2002-12-20 AU AU2002350352A patent/AU2002350352A1/en not_active Abandoned
- 2002-12-20 US US10/499,849 patent/US7625752B2/en not_active Expired - Fee Related
- 2002-12-20 WO PCT/CA2002/001979 patent/WO2003055989A2/fr active Application Filing
- 2002-12-20 AT AT02784995T patent/ATE464373T1/de not_active IP Right Cessation
-
2009
- 2009-11-06 US US12/613,821 patent/US20100104543A1/en not_active Abandoned
-
2012
- 2012-10-12 US US13/650,596 patent/US20130064801A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2470707A1 (fr) | 2003-07-10 |
US20130064801A1 (en) | 2013-03-14 |
EP1458854B1 (fr) | 2010-04-14 |
WO2003055989A2 (fr) | 2003-07-10 |
US7625752B2 (en) | 2009-12-01 |
US20050074435A1 (en) | 2005-04-07 |
EP1458854A2 (fr) | 2004-09-22 |
JP2005512592A (ja) | 2005-05-12 |
WO2003055989A3 (fr) | 2003-10-30 |
ATE464373T1 (de) | 2010-04-15 |
US20100104543A1 (en) | 2010-04-29 |
DE60236016D1 (de) | 2010-05-27 |
CA2470707C (fr) | 2014-07-08 |
AU2002350352A1 (en) | 2003-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL162648A0 (en) | Cellular compositions and methods of making and using them | |
SG149061A1 (en) | Definitive endoderm | |
WO2004046312A3 (fr) | Methodes de developpement in vitro de cellules souches hematopoietiques | |
GB2392674A (en) | Mesenchymal cells and osteoblasts from human embryonic stem cell | |
MXPA04006677A (es) | Procedimiento para la preparacion de esteres de escopina. | |
WO2005116073A3 (fr) | Endoderme exprimant pdx1 | |
EP1362093A4 (fr) | Production rapide d'anticorps monoclonaux | |
EP1553975A4 (fr) | Variants fc optimises et methodes destinees a leur generation | |
EP1360314A4 (fr) | Milieu chimiquement defini pour cellules mammaliennes cultivees | |
WO2005003320A3 (fr) | Differenciation neuronale de cellules souches | |
MX2021015070A (es) | Inmunomodulacion usando celulas madre de la placenta. | |
GB0109690D0 (en) | Improvements in or relating to compositions | |
AU1593001A (en) | Recombinant gelatin in vaccines | |
UA81398C2 (en) | Keratinocytes which may be used as biologically active substances for the treatment of wounds | |
IL196900A0 (en) | Autologous t-cell vaccines compositions | |
BR0206164A (pt) | Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida | |
MXPA04004939A (es) | 5,5??,6,6??,7,7??,8,8??-octahidro-2,2??-binaftoles 3-alquilados y 5,5??,6,6??,7,7??,8,8??-octahidro-2,2??-binaftoles 3,3??-dialquilados y procesos para su fabricacion. | |
AU2002310321A1 (en) | Compositions and methods for high-level, large-scale production of recombinant proteins | |
ATE371631T1 (de) | Glasszusammensetzung zur herstellung ultrafeiner fasern | |
WO2003010288A3 (fr) | Systeme d'expression de levure, methodes permettant de produire des polypeptides dans la levure et compositions relatives a ces systemes d'expression | |
IN266744B (fr) | ||
WO2002010337A3 (fr) | Methode de clonage de porcs | |
AU2002353775A1 (en) | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates | |
PT1451302E (pt) | Folhas reconstituídas in vitro de epitélio corneal humano e método de produção das mesmas | |
TW200626074A (en) | Fermented milk and process for producing the same |